Drilling down on drug prices

<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.loc.gov/MARC21/slim http://www.loc.gov/standards/marcxml/schema/MARC21slim.xsd">
  <record>
    <leader>00000cab a2200000   4500</leader>
    <controlfield tag="001">MAP20190021326</controlfield>
    <controlfield tag="003">MAP</controlfield>
    <controlfield tag="005">20190715150850.0</controlfield>
    <controlfield tag="008">190710e20190507usa|||p      |0|||b|eng d</controlfield>
    <datafield tag="040" ind1=" " ind2=" ">
      <subfield code="a">MAP</subfield>
      <subfield code="b">spa</subfield>
      <subfield code="d">MAP</subfield>
    </datafield>
    <datafield tag="084" ind1=" " ind2=" ">
      <subfield code="a">931</subfield>
    </datafield>
    <datafield tag="100" ind1="1" ind2=" ">
      <subfield code="0">MAPA20190009621</subfield>
      <subfield code="a">Passwater, Keith</subfield>
    </datafield>
    <datafield tag="245" ind1="0" ind2="0">
      <subfield code="a">Drilling down on drug prices</subfield>
      <subfield code="c">Keith Passwater, Dave Nelson</subfield>
    </datafield>
    <datafield tag="300" ind1=" " ind2=" ">
      <subfield code="a">8 p. </subfield>
    </datafield>
    <datafield tag="520" ind1=" " ind2=" ">
      <subfield code="a">Extending life and improving quality of life for literally millions, drug treatments such as aspirin, penicillin, insulin, AZT, cancer drug Herceptin, Harvoni, and Lipitor are nothing short of miracle drugs. Recently developed therapies are also impressive, such as single-dose Kymriah, which has an unprecedented 83 percent remission rate for children with acute lymphoblastic leukemia.[1] Another example is the newly available gene therapy Luxturna, which can cure blindness in carefully selected patients. Such therapies can achieve outcomes that are truly miraculous for those cured patients; they can also be staggeringly expensive. While anyone with a heart would agree that these miracle drug benefits are wonderful for patients, we need to find ways to harness these invaluable benefits while also finding ways to curb the growth in drug costs in the U.S. for all partiesconsumers, payers, and manufacturers alike. </subfield>
    </datafield>
    <datafield tag="650" ind1=" " ind2="4">
      <subfield code="0">MAPA20080606633</subfield>
      <subfield code="a">Industria farmacéutica</subfield>
    </datafield>
    <datafield tag="650" ind1=" " ind2="4">
      <subfield code="0">MAPA20080579784</subfield>
      <subfield code="a">Costes económicos</subfield>
    </datafield>
    <datafield tag="650" ind1=" " ind2="4">
      <subfield code="0">MAPA20080621919</subfield>
      <subfield code="a">Precios de los medicamentos</subfield>
    </datafield>
    <datafield tag="700" ind1="1" ind2=" ">
      <subfield code="0">MAPA20080051983</subfield>
      <subfield code="a">Nelson, Dave</subfield>
    </datafield>
    <datafield tag="773" ind1="0" ind2=" ">
      <subfield code="w">MAP20190020794</subfield>
      <subfield code="t">Contingencies : American Academy of Actuaries</subfield>
      <subfield code="d">Washington : American Academy of Actuaries, 2019-2024</subfield>
      <subfield code="g">07/05/2019 Año 2019 - May-June , p. 38-45</subfield>
    </datafield>
  </record>
</collection>